Clinical Trial Update: Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Bardoxolone Methyl on eGFR in patients with type 2 diabetes and chronic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Diabetic Nephropathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• Bardoxolone Methyl (bardoxolone methyl)

Snippet

Sponsor: Biogen | Conditions: Chronic Kidney Disease, Type 2 Diabetes | Phase 2 | Status: COMPLETED